EUVIMEDEUVIMED entdecken
Open Access

Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy

James D Phelan, Sebastian Scheich, Jaewoo Choi, George W Wright, Björn Häupl, Ryan M Young, Sara A Rieke, Martine Pape, Yanlong Ji, Henning Urlaub, Arnold Bolomsky, Carmen Doebele und 21 weitere

Cancer Cell · 2024

DOI: 10.1016/j.ccell.2023.12.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024. Verfasst von James D Phelan und 32 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Tyrosine Kinase Inhibitors, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, NCI NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton's tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and are particularly effective in certain molecular subtypes of DLBCL that rely on chronic active BCR signaling to promote oncogenic NF-κB. The MCD genetic subtype, which often acquires mutations in the BCR subunit, CD79B, and in the innate immune adapter, MYD88L265P, typically resists chemotherapy but responds exceptionally to BTK inhibitors. However, the underlying mechanisms of response to BTK inhibitors are poorly understood. Herein, we find a non-canonical form of chronic selective autophagy in MCD DLBCL that targets ubiquitinated MYD88L265P for degradation in a TBK1-dependent manner. MCD tumors acquire genetic and epigenetic alterations that attenuate this autophagic tumor suppressive pathway. In contrast, BTK inhibitors promote autophagic degradation of MYD88L265P, thus explaining their exceptional clinical benefit in MCD DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tyrosine Kinase InhibitorsLymphoma, Large B-Cell, DiffuseHumansMyeloid Differentiation Factor 88Signal TransductionAutophagy

Stichwörter der Autor:innen

Bruton’s tyrosine kinaseDLBCLautophagyfunctional genomicsproteomicstargeted therapy

Substanzen

Tyrosine Kinase InhibitorsMyeloid Differentiation Factor 88

Autor:innen und Institutionen

  • Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Goethe University Frankfurt, University Hospital, 60590 Frankfurt am Main, Germany; German Cancer Consorti…
  • Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD 20850, USA.
  • Goethe University Frankfurt, University Hospital, 60590 Frankfurt am Main, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, 60528 Frankfurt am Main, Germany; Frankfurt Cancer Institute, Goethe Uni…
  • Goethe University Frankfurt, University Hospital, 60590 Frankfurt am Main, Germany; Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt am Main, Germany.
  • Goethe University Frankfurt, University Hospital, 60590 Frankfurt am Main, Germany; Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt am Main, Germany; Bioanalytical Mass Spectrometry Group, Max Planck Inst…

Förderung

  • Medical Research Council
  • NCI NIH HHS
  • Wellcome Trust
  • NIGMS NIH HHS
  • Intramural NIH HHS
  • NIHR Cambridge Biomedical Research Centre
  • Wellcome-MRC Cambridge Stem Cell Institute
  • CRUK

Zitieren

APA

Phelan, J. D., Scheich, S., Choi, J., Wright, G. W., Häupl, B., Young, R. M., Rieke, S. A., Pape, M., Ji, Y., Urlaub, H., Bolomsky, A., Doebele, C., Zindel, A., Wotapek, T., Kasbekar, M., Collinge, B., Huang, D. W., Coulibaly, Z. A., Morris, V. M., …, & Oellerich, T. (2024). Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.12.019

Vancouver

Phelan JD, Scheich S, Choi J, Wright GW, Häupl B, Young RM, et al. Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer Cell. 2024. doi:10.1016/j.ccell.2023.12.019

BibTeX
@article{Phelan2024,
  author = {Phelan, James D and Scheich, Sebastian and Choi, Jaewoo and Wright, George W and Häupl, Björn and Young, Ryan M and Rieke, Sara A and Pape, Martine and Ji, Yanlong and Urlaub, Henning and Bolomsky, Arnold and Doebele, Carmen and Zindel, Alena and Wotapek, Tanja and Kasbekar, Monica and Collinge, Brett and Huang, Da Wei and Coulibaly, Zana A and Morris, Vivian M and Zhuang, Xiaoxuan and Enssle, Julius C and Yu, Xin and Xu, Weihong and Yang, Yandan and Zhao, Hong and Wang, Zhuo and Tran, Andy D and Shoemaker, Christopher J and Shevchenko, Galina and Hodson, Daniel J and Shaffer, Arthur L and Staudt, Louis M and Oellerich, Thomas},
  title = {Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy},
  journal = {Cancer Cell},
  year = {2024},
  doi = {10.1016/j.ccell.2023.12.019}
}
Kostenlos starten →